Trial Profile
A Phase I/II, Open Label, Dose-Escalating Study Evaluating the Safety and Efficacy of the Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody EMD 72000 (Matuzumab) in Combination with the EGFR Tyrosine Kinase Inhibitor Tarceva (Erlotinib) in Subjects with Recurrent Advanced Non-Small-Cell Lung Cancer.
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 31 May 2011
Price :
$35
*
At a glance
- Drugs Matuzumab (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors Merck KGaA
- 31 May 2011 New trial record